Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer
Breast Cancer Res
.
2024 May 24;26(1):83.
doi: 10.1186/s13058-024-01833-6.
Authors
Samuel A Jacobs
1
,
Ying Wang
2
,
Jame Abraham
2
3
,
Huichen Feng
2
,
Alberto J Montero
2
3
4
,
Corey Lipchik
2
,
Melanie Finnigan
2
,
Rachel C Jankowitz
2
5
6
,
Mohamad A Salkeni
2
7
8
,
Sai K Maley
2
,
Shannon L Puhalla
2
9
10
,
Fanny Piette
11
,
Katie Quinn
12
,
Kyle Chang
12
,
Rebecca J Nagy
12
,
Carmen J Allegra
2
13
,
Kelly Vehec
2
,
Norman Wolmark
2
9
,
Peter C Lucas
2
9
10
14
,
Ashok Srinivasan
2
15
,
Katherine L Pogue-Geile
2
Affiliations
1
NSABP Foundation, Pittsburgh, PA, USA. jacobssa1945@gmail.com.
2
NSABP Foundation, Pittsburgh, PA, USA.
3
Cleveland Clinic, Taussig Cancer Institute, Weston, Cleveland, OH, USA.
4
University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
5
University of Pittsburgh, Pittsburgh, PA, USA.
6
University of Pennsylvania Perelman School of Medicine, State College, Philadelphia, PA, USA.
7
National Institutes of Health, Washington, DC, USA.
8
Virginia Cancer Specialists, Fairfax, VA, USA.
9
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
10
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
11
International Drug Development Institute, Louvain-la-Neuve, Belgium.
12
Guardant Health, Redwood City, CA, USA.
13
University of Florida Health, Gainesville, FL, USA.
14
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
15
Autism Impact Fund, Pittsburgh, PA, USA.
PMID:
38790033
PMCID:
PMC11127282
DOI:
10.1186/s13058-024-01833-6
No abstract available
Publication types
Published Erratum